Key result
Gene therapy is emerging as a promising treatment for cardiomyopathies, with recent approvals for cardiac amyloidosis and Duchenne muscular dystrophy and ongoing trials for other rare heart diseases.
Why the study?
Cardiomyopathy treatment has historically focused solely on symptom management rather than targeting the underlying genetic pathophysiology.
Gene therapy is emerging as a promising pathophysiological treatment for various cardiomyopathies, with recent approvals and ongoing clinical trials highlighting its potential.
No takes yet. Share an insight, caveat, or question.
Recent approvals may expand options in rare cardiomyopathies; leaves open need for randomized data on durability and broader use.
Venturiello et al. (2024) conducted a review in Cardiomyopathies. Gene therapy was evaluated. Gene therapy is emerging as a promising treatment for cardiomyopathies, with recent approvals for cardiac amyloidosis and Duchenne muscular dystrophy and ongoing trials for other rare heart diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: